| What? | Treating cancer by taking advantage of the high load of endogenous DNA damage and oxidative stress in cancer cells. | Treating diseases caused by inflammation and fibrosis, e.g. pulmonary fibrosis, via DNA damage response pathways. |
| Problem today? | Cancers are heterogenous both between cancer indications and within same indication. Resistance development. Poor tolerability. | Treatment for these diseases are unsatisfactory. Risk for major loss of organ function, increased mortality and high costs for society. |
| Oxcia’s solution | OXC-101 ensures that cancer cells cannot repair the DNA and oxygen damage, so the cancer cell cannot grow and subsequently dies. | OGG1 inhibitor stops the inflammatory response as well as the fibrosis production and hence the disease. |
| Benefits | Targets cancer cell phenotype, rather than oncogene or tumour suppressor gene. Healthy cells are not affected. Makes cold tumours hot. Low resistance development. | Potential to cure the disease, not only addressing the symptoms. |
